Funding Opportunities

Open Programs

• The Edmond J. Safra Fellowship in Movement Disorders

  Objective:

  The Edmond J. Safra Fellowship in Movement Disorders aims to grow the global base of movement disorder specialists — neurologists with additional training in Parkinson's disease and other movement disorders — by training movement disorder clinician-researchers who can provide expert care and lead scientific advances.

  Award Amount:

  $90,000 per fellow per year

  Due Date:

  December 9, 2021

  Learn more

Programs in Review

• ASAP Collaborative Research Network: Circuitry and Brain-body Interactions

  

  Objective:

  The ASAP Collaborative Research Network, a program of the Aligning Science Across Parkinson’s (ASAP) initiative being implemented through The Michael J. Fox Foundation, seeks to support multidisciplinary, multi-institutional research teams to address key knowledge gaps in the basic mechanisms that contribute to Parkinson’s development and progression.

  Award Amount:

  Up to $9 million

  Due Date:

  Pre-proposals Due: December 2020

  Learn more
• Promoting Diversity, Equity and Inclusion in Parkinson’s Disease Research

  Objective:

  The Michael J. Fox Foundation seeks applications with the potential to increase knowledge about Parkinson’s disease in populations that have been excluded from or underrepresented in research.

  Award Amount:

  $50,000 up to $400,000 for 18 to 36 months

  Due Date:

  Pre-Proposals: April 2021

  Learn more
• Alpha-synuclein Seed Amplification Assay Program

  Objective:

  This program supports research that will facilitate integration of alpha-synuclein seed amplification assays into clinical studies for the purposes of predicting prognosis, tracking disease progression and monitoring therapeutic response.

  Award Amount:

  $3M for Total Program

  Due Date:

  September 13, 2021

  Learn more
• Therapeutic Pipeline Program: Pre-clinical Studies

  Objective:

  This funding program — an Edmond J. Safra Core Program for PD Research — will support development of Parkinson’s disease (PD) therapeutics with potential for fundamentally altering disease course or significantly improving non-motor or motor symptoms.

  Award Amount:

  Up to $500,000

  Due Date:

  Pre-proposals Due: September 28, 2021

  Learn more
• Target Advancement: Tool Generation and Target Validation

  Objective:

  This funding program — an Edmond J. Safra Core Program for PD Research — seeks to build conclusive evidence and develop field-enabling tools around early-stage biological targets in Parkinson’s disease (PD).

  Award Amount:

  Up to $200,000

  Due Date:

  Pre-proposals Due: September 28, 2021

  Learn more
• Cellular Phenotyping in Human iPSCs

  Objective:

  This program will support phenotyping of human induced pluripotent stem cells (iPSCs) from our Parkinson’s Progression Markers Initiative (PPMI). Such work will facilitate future mechanistic studies and expedite drug screening and proof-of-concept testing for Parkinson’s therapeutics.

  Award Amount:

  Up to $200,000 (data analysis) or up to $1 million (phenotypic analysis)

  Due Date:

  September 28, 2021

  Learn more
• Parkinson’s Pathway Molecular Data Analysis

  Objective:

  This funding program will support high-impact projects that utilize existing data resources to increase molecular understanding of Parkinson’s disease (PD), correlate biological changes to clinical/other outcomes, and more deeply interrogate disrupted pathways in PD.

  Award Amount:

  Up to $350,000

  Due Date:

  Pre-proposals Due: September 28, 2021

  Learn more
• MRI Biomarkers: Data Analysis and Tool Generation

  Objective:

  This funding program will support studies to develop reproducible diagnostic, prognostic, and monitoring magnetic resonance imaging (MRI) biomarkers.

  Award Amount:

  $5M for Total Program

  Due Date:

  Pre-proposals Due: September 28, 2021

  Learn more

Closed Programs

• Therapeutic Pipeline Program

  Objective:

  The Michael J. Fox Foundation funds work with potential for fundamentally altering disease course and/or significantly improving treatment of symptoms above and beyond current standards of care.

  Award Amount:

  Up to $500,000 (pre-clinical) or up to $2 million (clinical)

  Due Date:

  Funded Summer 2021

  Learn more
• Target Advancement Program

  Objective:

  The Michael J. Fox Foundation funds work that leverages and translates basic research to enable therapeutic development.

  Award Amount:

  Up to $150,000 for 18 to 24 months

  Due Date:

  Funded Summer 2021

  Learn more
• Development and Validation of Improved Outcome Measures

  Objective:

  This program funds work to develop objective biomarkers that can support therapeutic development in Parkinson’s.

  Award Amount:

  Up to $750,000 for up to two years

  Due Date:

  Funded Summer 2020

  Learn more
• Analysis of Patient-Reported Outcomes from Fox Insight

  Objective:

  This program funds analyses of the patient-reported outcomes (PROs) and genetic data collected through the Fox Insight study.

  Award Amount:

  Up to $100,000 for one year grants

  Due Date:

  Funded Summer 2021

  Learn more
• PIPETTE: 4R Tau and Alpha-Synuclein PET Tracer Development

  Objective:

  The PIPETTE Consortium (Philanthropic Investments in PET TracErs) is a funding partnership formed in 2017 by The Michael J. Fox Foundation and Rainwater Charitable Foundation (conveners of the Tau Consortium).

  Award Amount:

  Total funding available is $1 million

  Due Date:

  Awarded Summer 2021

  Learn more
• Investigating Environmental Factors that Increase the Risk for Parkinson’s Disease

  Objective:

  This funding program supported projects to investigate environmental exposures, such as chemicals or toxic emissions, that increase the risk of PD and/or influence disease progression.

  Award Amount:

  Up to $400,000 for up to two years

  Due Date:

  Awarded Spring 2021

  Learn more
• Parkinson’s Pathway Biomarkers

  Objective:

  The Michael J. Fox Foundation seeks applications with the potential to develop new/better biomarkers for measuring pathway function or dysfunction that can support therapeutic development for affected pathways in Parkinson’s disease (PD).

  Award Amount:

  Up to $300,000

  Learn more
• Ken Griffin Alpha-synuclein Imaging Competition

  

  Objective:

  The Michael J. Fox Foundation has prioritized alpha-synuclein imaging as the most likely imaging approach to have an impact for therapeutic development. The goal of this $10-million funding program is to deliver a selective alpha-synuclein PET tracer for use in clinical studies.

  Award Amount:

  Initial $8.5M Total with Additional Future $1.5M

  Due Date:

  Awarded Summer 2020

  Learn more